Jump to section
To translate critical scientific advancements in aging research into accessible health products and technologies.
Elysium is led by, and works with a network of, decorated scientists to produce health supplements which mostly target anti-ageing and immune health. Its first product, Basis, hit the headlines for its focus on supporting long term health at a cellular level by increasing NAD+ levels, a coenzyme which plays a huge role in bodily function yet decreases with age.
While there is no pill for eternal youth, a proven method for slowing down the ageing process would no doubt prove extremely popular. While Elysium’s product has been shown to increase NAD+ levels by a significant amount, the jury is still out on whether they actually work to extend lifespan.
That said, the fact that the company was co-founded by Leonard P. Guarente – an MIT biologist best known for his research on life span extension, adds plenty of weight to its reputation.
With plenty of funding already secured from investors which include Mayo Clinic Ventures, Elysium is now aiming to expand its product portfolio while growing its customer base.
Kirsty
Company Specialist at Welcome to the Jungle
Dec 2019
$40m
SERIES C
Dec 2016
$20m
SERIES B
This company has top investors
Leonard Guarente, PhD
(Chief Scientist)Novartis Professor of Biology at MIT. Since 2008 they have led the Glenn Center for the Biology of Aging Research at MIT, where focusing on the genetic and molecular basis of aging — first in model organisms and now in mouse models and humans.
Eric Marcotulli
(CEO)Before co-founding Elysium Health in 2012, they were Sequoia Capitals youngest partner, leading growth investing in mobile technologies. Prior to this they were an associate at Bain Capital Ventures.
Dan Alminana
(COO)Began finance career as a consultant at Deloitte and an associate in Citi Smith Barney’s venture capital coverage group. Prior to co-founding Elysium Health, they served as vice president at JP Morgan Securities.
Software Engineering